Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis.
Claudication
Diabetes complications
Diabetes-associated trophic ulcers
Efficacy
Meta-analysis
Nephropathy
Peripheral arterial disease
Retinopathy
Sulodexide
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
07
12
2020
accepted:
06
01
2021
pubmed:
28
1
2021
medline:
15
4
2021
entrez:
27
1
2021
Statut:
ppublish
Résumé
Micro- and macrovascular complications of diabetes are leading morbidities in the world population. They are responsible not only for increased mortality but also severe disabilities, which jeopardize quality of life (e.g., blindness, walking limitations, and renal failure requiring dialysis). The new antidiabetic agents (e.g., glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter inhibitors) are increasingly recognized as breakthrough agents in the treatment of diabetes and prevention of diabetic complications. However, drugs effective in preventing and treating diabetic disabilities are still needed and sulodexide could be one of those able to address the unmet clinical needs of the new antidiabetic agents. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the World Health Organization (WHO) International Clinical Trials Registry Platform Search Portal. We also manually searched potentially relevant journals, conference proceedings, and journal supplements. Any study monitoring any effect of sulodexide in subjects with diabetes, in relation to renal, vascular, and ocular complication, was considered. Treatment effects were estimated using standardized mean differences (SMDs), mean differences (MDs), and risk ratios (RRs), as appropriate. We calculated 95% confidence interval (CIs) and heterogeneity (Q, tau, and I The search found 45 studies with 2817 participants (mean age 57 years; 63% male). The 26 randomized controlled studies included 2074 participants (mean age 58.8 years; 66% male). Sulodexide reduced the impact of diabetic retinopathy; increased the pain-free and maximal walking distance in peripheral arterial disease; accelerated the healing of diabetes-associated trophic ulcers; and decreased the rate of albumin excretion in subjects with nephropathy. The risk of adverse events (AEs) was not different between sulodexide and controls. Sulodexide has a beneficial effect on the ocular, peripheral arterial disease, trophic ulcers, and renal complications of diabetes without increasing the risk of AEs.
Identifiants
pubmed: 33502688
doi: 10.1007/s12325-021-01620-1
pii: 10.1007/s12325-021-01620-1
pmc: PMC7932977
doi:
Substances chimiques
Glycosaminoglycans
0
Hypoglycemic Agents
0
glucuronyl glucosamine glycan sulfate
75HGV0062C
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Pagination
1483-1513Références
DeFronzo RA, Ferrannini E, Zimmet P, Alberti KGMM. International textbook of diabetes mellitus. 4th ed. Hoboken: Wiley-Blackwell; 2015.
doi: 10.1002/9781118387658
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–30. https://doi.org/10.1016/S0140-6736(16)00618-8 .
doi: 10.1016/S0140-6736(16)00618-8
International Diabetes Federation. IDF Diabetes Atlas, 8th edition 2017. http://www.diabetesatlas.org . Accessed 9 Apr 2020.
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858. https://doi.org/10.1016/S0140-6736(18)32279-7 .
doi: 10.1016/S0140-6736(18)32279-7
Hewitt J, Castilla Guerra L, Fernández-Moreno MC, Sierra C. Diabetes and stroke prevention: a review. Stroke Res Treat. 2012;2012:673187. https://doi.org/10.1155/2012/673187 .
doi: 10.1155/2012/673187
pubmed: 23326760
pmcid: 3543806
Thiruvoipati T, Kielhorn CE, Armstrong EJ. Peripheral artery disease in patients with diabetes: epidemiology, mechanisms, and outcomes. World J Diabetes. 2015;6(7):961–9. https://doi.org/10.4239/wjd.v6.i7.961 .
doi: 10.4239/wjd.v6.i7.961
pubmed: 26185603
pmcid: 4499529
Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431–7. https://doi.org/10.1016/S2213-8587(17)30104-3 .
doi: 10.1016/S2213-8587(17)30104-3
pubmed: 28365411
pmcid: 28365411
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–91. https://doi.org/10.1056/NEJMoa0706245 .
doi: 10.1056/NEJMoa0706245
pubmed: 18256393
pmcid: 18256393
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/NEJMoa1611925 .
doi: 10.1056/NEJMoa1611925
pubmed: 28605608
pmcid: 28605608
Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32(4):219–26. https://doi.org/10.1007/BF00285287 .
doi: 10.1007/BF00285287
pubmed: 2668076
pmcid: 2668076
Dogné S, Flamion B, Caron N. Endothelial glycocalyx as a shield against diabetic vascular complications: involvement of hyaluronan and hyaluronidases. Arterioscler Thromb Vasc Biol. 2018;38(7):1427–39. https://doi.org/10.1161/ATVBAHA.118.310839 .
doi: 10.1161/ATVBAHA.118.310839
pubmed: 29880486
pmcid: 6039403
Abaterusso C, Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol. 2006;5(4):211–22. https://doi.org/10.2165/00024677-200605040-00002 .
doi: 10.2165/00024677-200605040-00002
pubmed: 16879000
pmcid: 16879000
Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs. 2007;67(18):2681–96. https://doi.org/10.2165/00003495-200767180-00004 .
doi: 10.2165/00003495-200767180-00004
pubmed: 18062718
pmcid: 18062718
Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care. 2008;31(Suppl 2):S202–7. https://doi.org/10.2337/dc08-s251 .
doi: 10.2337/dc08-s251
pubmed: 18227486
pmcid: 18227486
Masola V, Zaza G, Gambaro G. Sulodexide and glycosaminoglycans in the progression of renal disease. Nephrol Dial Transplant. 2014;29(Suppl 1):i74–9. https://doi.org/10.1093/ndt/gft389 .
doi: 10.1093/ndt/gft389
pubmed: 24493873
pmcid: 24493873
Masola V, Zaza G, Onisto M, Lupo A, Gambaro G. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014;33(3):243–54.
pubmed: 24936533
pmcid: 24936533
Carroll BJ, Piazza G, Goldhaber SZ. Sulodexide in venous disease. J Thromb Haemost. 2019;17(1):31–8. https://doi.org/10.1111/jth.14324 .
doi: 10.1111/jth.14324
pubmed: 30394690
pmcid: 30394690
Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Dev Ther. 2013;8:49–65. https://doi.org/10.2147/DDDT.S6762 .
doi: 10.2147/DDDT.S6762
Yung S, Chau MK, Zhang Q, Zhang CZ, Chan TM. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One. 2013;8(1):e54501. https://doi.org/10.1371/journal.pone.0054501 .
doi: 10.1371/journal.pone.0054501
pubmed: 23349910
pmcid: 3551764
Roshan-Milani S, Khalilpour J, Abdollahzade FA. The heparanase inhibitor (sulodexide) decreases urine glycosaminoglycan excretion and mitigates functional and histological renal damages in diabetic rats. Acta Med Bulg. 2019;46(2):41–6. https://doi.org/10.2478/amb-2019-0017 .
doi: 10.2478/amb-2019-0017
Gambaro G, Cavazzana AO, Luzi P, et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 1992;42(2):285–91. https://doi.org/10.1038/ki.1992.288 .
doi: 10.1038/ki.1992.288
pubmed: 1328749
pmcid: 1328749
Gambaro G, Venturini AP, Noonan DM, et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 1994;46(3):797–806. https://doi.org/10.1038/ki.1994.335 .
doi: 10.1038/ki.1994.335
pubmed: 7527876
pmcid: 7527876
Kristová V, Lísková S, Sotníková R, Vojtko R, Kurtanský A. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res. 2008;57(3):491–4.
pubmed: 18597586
pmcid: 18597586
Li T, Liu X, Zhao Z, Ni L, Liu C. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model. Oncotarget. 2017;8(53):91350–61. https://doi.org/10.18632/oncotarget.20518 .
doi: 10.18632/oncotarget.20518
pubmed: 29207649
pmcid: 5710929
Liu YN, Zhou J, Li T, et al. Sulodexide protects renal tubular epithelial cells from oxidative stress-induced injury via upregulating klotho expression at an early stage of diabetic kidney disease. J Diabetes Res. 2017;2017:4989847. https://doi.org/10.1155/2017/4989847 .
doi: 10.1155/2017/4989847
pubmed: 28929120
pmcid: 5591972
Song JW, Zullo JA, Liveris D, Dragovich M, Zhang XF, Goligorsky MS. Therapeutic restoration of endothelial glycocalyx in sepsis. J Pharmacol Exp Ther. 2017;361(1):115–21. https://doi.org/10.1124/jpet.116.239509 .
doi: 10.1124/jpet.116.239509
pubmed: 28167639
pmcid: 5363766
Li T, Liu C. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model. Int Angiol. 2018;37:72.
Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010;53(12):2646–55. https://doi.org/10.1007/s00125-010-1910-x .
doi: 10.1007/s00125-010-1910-x
pubmed: 20865240
pmcid: 2974920
Mannello F, Ligi D, Raffetto JD. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol. 2014;33(3):236–42.
pubmed: 24936532
pmcid: 24936532
Mannello F, Ligi D, Canale M, Raffetto JD. Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease. Curr Vasc Pharmacol. 2014;12(1):173–85. https://doi.org/10.2174/1570161111666131126144025 .
doi: 10.2174/1570161111666131126144025
pubmed: 24279420
Ligi D, Mosti G, Croce L, Raffetto JD, Mannello F. Chronic venous disease—part I: inflammatory biomarkers in wound healing. Biochim Biophys Acta. 2016;1862(10):1964–74. https://doi.org/10.1016/j.bbadis.2016.07.018 .
doi: 10.1016/j.bbadis.2016.07.018
pubmed: 27478145
Ligi D, Mosti G, Croce L, Raffetto JD, Mannello F. Chronic venous disease—part II: proteolytic biomarkers in wound healing. Biochim Biophys Acta. 2016;1862(10):1900–8. https://doi.org/10.1016/j.bbadis.2016.07.011 .
doi: 10.1016/j.bbadis.2016.07.011
pubmed: 27460704
Ligi D, Benitez S, Croce L, et al. Electronegative LDL induces MMP-9 and TIMP-1 release in monocytes through CD14 activation: inhibitory effect of glycosaminoglycan sulodexide. Biochim Biophys Acta Mol Basis Dis. 2018;1864(12):3559–67. https://doi.org/10.1016/j.bbadis.2018.09.022 .
doi: 10.1016/j.bbadis.2018.09.022
pubmed: 30254012
Shu J, Zeng LY, Lin KY, et al. Renal protective effects of sulodexide in diabetic rats and its anti-oxidative mechanism. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29(4):778–80.
pubmed: 19403420
Gabryel B, Jarząbek K, Machnik G, et al. Superoxide dismutase 1 and glutathione peroxidase 1 are involved in the protective effect of sulodexide on vascular endothelial cells exposed to oxygen-glucose deprivation. Microvasc Res. 2016;103:26–35. https://doi.org/10.1016/j.mvr.2015.10.001 .
doi: 10.1016/j.mvr.2015.10.001
pubmed: 26477504
De Felice F, Megiorni F, Pietrantoni I, et al. Sulodexide counteracts endothelial dysfunction induced by metabolic or non-metabolic stresses through activation of the autophagic program. Eur Rev Med Pharmacol Sci. 2019;23(6):2669–80. https://doi.org/10.26355/eurrev_201903_17415 .
doi: 10.26355/eurrev_201903_17415
pubmed: 30964194
Masola V, Onisto M, Zaza G, Lupo A, Gambaro G. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med. 2012;10:213. https://doi.org/10.1186/1479-5876-10-213 .
doi: 10.1186/1479-5876-10-213
pubmed: 23095131
pmcid: 3562257
Xu G, Qin Q, Yang M, Qiao Z, Gu Y, Niu J. Heparanase-driven inflammation from the AGEs-stimulated macrophages changes the functions of glomerular endothelial cells. Diabetes Res Clin Pract. 2017;124:30–40. https://doi.org/10.1016/j.diabres.2016.12.016 .
doi: 10.1016/j.diabres.2016.12.016
pubmed: 28081450
Giurdanella G, Lazzara F, Caporarello N, et al. Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE. Biochem Pharmacol. 2017;142:145–54. https://doi.org/10.1016/j.bcp.2017.06.130 .
doi: 10.1016/j.bcp.2017.06.130
pubmed: 28651842
Matuska J, Benova K. Development of wall stiffness parameters in diabetes mellitus type II—evaluation of therapeutic effect of sulodexide vs naftidrofuryl: an open controlled 2-year study. Vasa-Eur J Vasc Med. 2017;46:30. https://doi.org/10.1024/0301-1526/a000651 .
doi: 10.1024/0301-1526/a000651
Cha JJ, Kang YS, Hyun YY, et al. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats. Life Sci. 2013;92(23):1118–24. https://doi.org/10.1016/j.lfs.2013.04.008 .
doi: 10.1016/j.lfs.2013.04.008
pubmed: 23643633
Tiurenkov IN, Voronkov AV, Slietsans AA, Snigur GL. Effects of mexidol and sulodexide on the level of specific markers of endothelial dysfunction in animals with experimental diabetes mellitus. Eksp Klin Farmakol. 2012;75(5):14–6.
pubmed: 22834122
Raffetto JD, Calanni F, Mattana P, Khalil RA. Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway. Biochem Pharmacol. 2019;166:347–56. https://doi.org/10.1016/j.bcp.2019.04.021 .
doi: 10.1016/j.bcp.2019.04.021
pubmed: 31014752
pmcid: 6602837
Condorelli M, Chiariello M, Dagianti A, et al. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol. 1994;23(1):27–34. https://doi.org/10.1016/0735-1097(94)90498-7 .
doi: 10.1016/0735-1097(94)90498-7
pubmed: 8277091
Peterkova V, Mishina I, Sherbacheva L. Sulodexide in the treatment of diabetic nephropathy in children. Diabetes (Mosk). 1999;3:31–3.
Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions, version 6.0. New York: Wiley; 2019.
doi: 10.1002/9781119536604
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898 .
doi: 10.1136/bmj.l4898
Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153–60. https://doi.org/10.1136/ebmental-2019-300117 .
doi: 10.1136/ebmental-2019-300117
pubmed: 31563865
R Core Team. A language and environment for statistical computing. 2015. R foundation for statistical computation, Vienna, Austria. https://www.R-project.org/ . Accessed 17 Mar 2020.
Higgins JP, Li T, Deeks JJ, et al. Choosing effect measures and computing estimates of effect, version 6.0. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. Cochrane handbook for systematic reviews of interventions. New York: Wiley; 2019. p. 143–76.
doi: 10.1002/9781119536604.ch6
Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks: SAGE; 2001.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. https://doi.org/10.1186/1471-2288-14-135 .
doi: 10.1186/1471-2288-14-135
pubmed: 25524443
pmcid: 4383202
Chen S, Wei M, Gao Y, et al. A randomized controlled trial of sulodexide for early diabetic nephropathy. Chin J Evid Based Med. 2008;8(3):162–6. https://doi.org/10.7507/1672-2531.20080037 .
doi: 10.7507/1672-2531.20080037
Hu M, Lv B, Meng Y, Zhou J, Xu X, Xiao X. Therapeutic effects of sulodexide combined with irbesartan on elderly patients with diabetic nephropathy. Pract Geriatr. 2009;23(4):276–8.
Wang T-J, Wang Z-S, Yang F. Clinical observation of sulodexide in treatment of type 2 diabetes with early nephropathy. Med Pharm World. 2009;11:769–71.
Hu M, Lv B, Meng Y, Zhou J, Xu X, Xiao X. Therapeutic effects of perindopril combined with sulodexide on elderly early patients with diabetic nephropathy. Southwest Nat Defence Med. 2010;20:501–3.
Liu S. Therapeutic effects of sulodexide combined with benazapril on patients with diabetic kidney disease. Chin J Diffic Compl Cas. 2011;10:21–2.
Ma J, Jiang H, Cui Q, Song B. Clinical observation of sulodexide in reducing microalbumi-nuria in diabetic nephropathy patients. Mod Prev Med. 2011;38:2918–9.
Zhang H, Kang P, Li J, et al. Study of the effect of Chulo on albuminuria in diabetic nephropathy. Med J Integr Tradit Chin West Med. 2011;20:405–6.
Huo S, Huang M, Liu Y. Clinical observation of sulodexide in treatment of in reducing proteinuria in type 2 diabetic nephropathy patients. Hebei Med J. 2014;36:191–2.
Chen L, Yang R. Effect of sulodexide on urine protein excretion in type 2 diabetes with proteinuria. Med J Wuhan Univ. 2015;34:450–2.
Rubbi F, Caramazza R, Boccia S, et al. The effects of sulodexide on diabetic retinopathy. Minerva Cardioangiol. 2000;48(Suppl 1):81–2.
Shadrichev F. The effect of diabetic nephropathy therapy with “Vessel Due F” (sulodexide) on the risk of intraocular hemorrhages in patients with proliferative diabetic retinopathy. Ophthalmol Gazette. 2009;2(2):49–53.
Song JH, Chin HS, Kwon OW, Lim SJ, Kim HK, DRESS Research Group. Effect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS). Graefes Arch Clin Exp Ophthalmol. 2015;253(6):829–37. https://doi.org/10.1007/s00417-014-2746-8 .
doi: 10.1007/s00417-014-2746-8
pubmed: 25112845
Belcaro G, Dugall M, Bradford HD, et al. Recurrent retinal vein thrombosis: prevention with aspirin, Pycnogenol®, ticlopidine, or sulodexide. Minerva Cardioangiol. 2019;67(2):109–14. https://doi.org/10.23736/S0026-4725.19.04891-6 .
doi: 10.23736/S0026-4725.19.04891-6
pubmed: 30964246
Utratová J, Mayer J, Elbl L, Vorlícek J, Prásek J. Experience with sulodexide (Vessel Due F) in diabetics with ischemic disease of the lower extremities. Vnitr Lek. 1993;39(6):575–80.
pubmed: 8212613
Bregovsky V, Zalesskaya A. The use of sulodexide in obliterating atherosclerosis of the lower extremities in patients with diabetes mellitus. Prob Endocrinol. 1998;44(4):16–8.
doi: 10.14341/probl199844416-18
Koblik T, Sieradzki J, Sendur R, et al. The effect of insulin and sulodexide (Vessel Due F) on diabetic foot syndrome: pilot study in elderly patients. J Diabetes Complicat. 2001;15(2):69–74. https://doi.org/10.1016/s1056-8727(00)00134-3 .
doi: 10.1016/s1056-8727(00)00134-3
Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V, Arterial Arm of the Suavis (Sulodexide Arterial Venous Italian Study) Group. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J. 2002;23(13):1057–65. https://doi.org/10.1053/euhj.2001.3033 .
doi: 10.1053/euhj.2001.3033
pubmed: 12093059
Moldovan C, Marc F, Farcaş D. Sulodexide treatment in patients with type 2 diabetes mellitus and intermittent claudication. Eur J Int Med. 2011;22:S63.
doi: 10.1016/S0953-6205(11)60259-8
Katorkin SE. Significance of endothelial protection in treatment of patients with class c6 chronic venous disease and type 2 diabetes mellitus. Angiol Sosud Khir. 2015;21(3):99–102 (104–6).
pubmed: 26355928
pmcid: 26355928
Zakharova NO, Bulgakova SV, Katorkin SE, Melnikov MA, Treneva EV, Nikolaeva AV. The treatment of elderly and senile patients with venous trophic ulcers and type 2 diabetes mellitus. Adv Gerontol. 2017;30(6):917–24.
pubmed: 29608839
pmcid: 29608839
Solini A, Carraro A, Barzon I, Crepaldi G. Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin dependent diabetic patients with macroalbuminuria. Diabetes Nutr Metab. 1994;7(5):304–7.
Velussi M, Cernigoi A, Dapas F, De Monte A. Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus. Diabetes Nutr Metab. 1996;9(2):53–8.
Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant. 1997;12(11):2295–300. https://doi.org/10.1093/ndt/12.11.2295 .
doi: 10.1093/ndt/12.11.2295
pubmed: 9394314
pmcid: 9394314
Perušičová J, Škrha J. The effect of sulodexide, a glycosaminoglycan, on albuminuria in diabetic patients. Vnitr Lek. 1997;43(11):748–52.
pubmed: 9650507
pmcid: 9650507
Poplawska A, Szelachowska M, Topolska J, Wysocka-Solowie B, Kinalska I. Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res Clin Pract. 1997;38(2):109–14. https://doi.org/10.1016/s0168-8227(97)00096-x .
doi: 10.1016/s0168-8227(97)00096-x
pubmed: 9483374
pmcid: 9483374
Shestakova MV, Chugunova LA, Vorontsov AV, Dedov II. The efficacy of sulodexide—a low-molecular heparin—in the therapy of diabetic nephropathy. Ter Arkh. 1997;69(6):34–7.
pubmed: 9297270
pmcid: 9297270
Škrha J, Perušičová J, Pont’uch P, Okša A. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract. 1997;38(1):25–31. https://doi.org/10.1016/s0168-8227(97)00076-4 .
doi: 10.1016/s0168-8227(97)00076-4
pubmed: 9347243
pmcid: 9347243
Solini A, Vergnani L, Ricci F, Crepaldi G. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care. 1997;20(5):819–23. https://doi.org/10.2337/diacare.20.5.819 .
doi: 10.2337/diacare.20.5.819
pubmed: 9135948
pmcid: 9135948
Sorrenti G, Grimaldi M, Canova N, Palazzini E, Melchionda N. Glycosaminoglycans as a possible tool for micro- and macroalbuminuria in diabetic patients. A pilot study. J Int Med Res. 1997;25(2):81–6. https://doi.org/10.1177/030006059702500204 .
doi: 10.1177/030006059702500204
pubmed: 9100162
pmcid: 9100162
Szelachowska M, Poplawska A, Topolska J, Kinalska I, Grimaldi M. A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Curr Med Res Opin. 1997;13(9):539–45. https://doi.org/10.1185/03007999709113327 .
doi: 10.1185/03007999709113327
pubmed: 9169256
pmcid: 9169256
Rasovskiĭ BL, Tarasov AV, Trel’skaia N, Severina TI, Chernykh EF. Sulodexide in the treatment of diabetic nephropathy. Klin Med (Mosk). 1998;76(7):40–2.
Škrha J, Perušičová J, Kvasnička J, Hilgertová J. The effect of glycosaminoglycan sulodexide on oxidative stress and fibrinolysis in diabetes mellitus. Sb Lek. 1998;99(2):103–9.
pubmed: 10536489
pmcid: 10536489
Zalevskaia AG, Astamirova KhS, Karpova IA, Popova SG. A trial of the use of the low-molecular heparin sulodexide in the therapy of diabetic nephropathy. Ter Arkh. 1998;70(3):71–4.
pubmed: 9575594
pmcid: 9575594
Oksa A, Pontuch P, Kratochvilova H. The effect of glycosaminoglycan sulodexide on albuminuria in patients with diabetes mellitus. Bratisl Lek Listy. 1999;100(9):486–9.
pubmed: 10645038
pmcid: 10645038
Sun M, Tian L. Clinical study on type II diabetic nephropathy treated with sulodexide. Chi J Chin New Drugs J. 1999;8:408–10.
Lichiardopol R, Ionescu-Tirgoviste C, Serban V, Dumitrescu C, Mota M, Ghise G. The effect of sulodexide on albuminuria in a group of patients with diabetes. Rom J Diabetes Nutr Metab Dis. 2001;2:28–31.
Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002;13(6):1615–25. https://doi.org/10.1097/01.asn.0000014254.87188.e5 .
doi: 10.1097/01.asn.0000014254.87188.e5
pubmed: 12039991
pmcid: 12039991
Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2005;18(5):568–74.
pubmed: 16299683
pmcid: 16299683
Sulikowska B, Olejniczak H, Muszynska M, et al. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol. 2006;26(6):621–8. https://doi.org/10.1159/000098195 .
doi: 10.1159/000098195
pubmed: 17191008
pmcid: 17191008
Heerspink HL, Greene T, Lewis JB, et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant. 2008;23(6):1946–54. https://doi.org/10.1093/ndt/gfm893 .
doi: 10.1093/ndt/gfm893
pubmed: 18089623
pmcid: 18089623
Blouza S, Dakhli S, Abid H, et al. Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2010;23(4):415–24.
pubmed: 20175052
pmcid: 20175052
Mao L, Zhong X. Effect of sulodexide combined with benazepril on urinary albumin in patients with type 2 diabetes. Chin Mod Med. 2010;17:68–9.
Jian R, Jie S, Can H. Effect of sulodexide on microalbuminuria of the third stage of type 2 diabetic nephropathy. Mod Med J Chin. 2010;11:20.
Wang H. Effect of sulodexide in diabetic nephropathy. Prac J Med Pharm. 2010;27:315–6.
Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011;58(5):729–36. https://doi.org/10.1053/j.ajkd.2011.06.020 .
doi: 10.1053/j.ajkd.2011.06.020
pubmed: 21872376
pmcid: 21872376
He X, Ge Z. Curative effect of sulodexide in diabetic nephropathy patients. Clin Foc. 2012;27:1626–7.
Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23(1):123–30. https://doi.org/10.1681/ASN.2011040378 .
doi: 10.1681/ASN.2011040378
pubmed: 22034636
pmcid: 22034636
Kang Z. Study on effect of sulodexide in treatment of diabetic nephropathy stage III. Guide Chin Med. 2013;11:25–8.
Xiong Y. Treatment of sulodexide on albuminuria in early diabetic nephropathy. J Jianghan Univ (Nat Sci Ed). 2014;42(3):90–2.
Satirapoj B, Kaewput W, Supasyndh O, Ruangkanchanasetr P. Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: a randomized controlled trial. J Diabetes Res. 2015;2015:172038. https://doi.org/10.1155/2015/172038 .
doi: 10.1155/2015/172038
pubmed: 25918727
pmcid: 4396730
Zilişteanu DS, Atasie T, Voiculescu M. Efficacy of long-term low-dose sulodexide in diabetic and non-diabetic nephropathies. Rom J Intern Med. 2015;53(2):161–9. https://doi.org/10.1515/rjim-2015-0022 .
doi: 10.1515/rjim-2015-0022
pubmed: 26402986
pmcid: 26402986
Dakhli S, Khedher A, Borni Z, Achour A, Hachicha J. A clinical experience on sulodexide in the treatment of patients with diabetic nephropathy. J Nephrol Ther. 2016;7(1):1000284. https://doi.org/10.4172/2161-0959.1000284 .
doi: 10.4172/2161-0959.1000284
Li H, Ke W, Liu J, He X Jr, Liu L, Li Y. Effect of intravenous and oral therapy with sulodexide on diabetic nephropathy. Diabetes. 2017;66:A597.
Pisano L, Moronesi F, Falco F, et al. The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Controlled study in hyperlipidemic and diabetic subjects. Thromb Res. 1986;41(1):23–31. https://doi.org/10.1016/0049-3848(86)90276-8 .
doi: 10.1016/0049-3848(86)90276-8
pubmed: 3515614
pmcid: 3515614
Piva I, Lora L, Baso A, Erle G. Controlled study of the effect of sulodexide on peripheral diabetic macroangiopathy. G Clin Med. 1985;66(1–2):37–45.
pubmed: 3891485
pmcid: 3891485
Arsenio L, Strata A. Hyperlipidaemias in diabetes. Therapeutic effects of a parenterally administered glucosaminoglycan: sulodexide (Vessel Due). Clin Trials J. 1987;24:312–21.
Szafilk J, Kamińska A. Usefulness of Vessel Due F (sulodexide) in treatment of patients with diabetic retinopathy, senile macular degeneration and retinal vein occlusion. Okulistyka. 2000;3:1–4.
d’Aloia A, Dati M, Della Corte M, Romano M, Lanza M, Romano A. Assessment of the effectiveness of sulodexide on diabetic patients. Boll Oculistica. 2001;80(1):37–41.
Karimov K, Shakhmaliyeva A. Effect of sulodexide on non-proliferative diabetic retinopathy. Azerbaijan Med J. 2002;1:72–6.
Li R, Xing J, Mu X, et al. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther. 2015;9:6275–83. https://doi.org/10.2147/DDDT.S87973 .
doi: 10.2147/DDDT.S87973
pubmed: 26664049
pmcid: 4671764
Yan W, Zhou B, Shen Y, Xu G. Antioxidant and antithrombotic therapies for diabetic kidney disease. Iran J Kidney Dis. 2015;9(6):413–20.
pubmed: 26552346
pmcid: 26552346
Lamblova K, Mlcoch T, Mazalova M, Dolezal T. Cost-effectiveness analysis of sulodexide in patients with non-proliferative diabetic retinopathy in the Czech Republic. Value Health. 2016;19(7):A568.
doi: 10.1016/j.jval.2016.09.1283
Tokmakova AY, Milenkaya T, Chirkova L, Arbuzova M, Antsiferov M. The use of the drug Wessel Duet F in the complex treatment of lesions of the lower extremities in patients with type II diabetes. Prob Endocrinol. 1999;45(3):14–8.
doi: 10.14341/probl11760
Klisarova A, Bihchelian H, Koeva L. Planary bone scintigraphy of the foot in the diabetics with peripheral macroangiopathy, treated with sulodexide (Vessel Due F). Rentgenol Radiol. 2000;39(4):281–4.
Svetukhin AM, Zemlianoĭ AB, Orudzheva SA, et al. Experience in the use of vessel due F (sulodexide) in patients with suppurative-necrotic forms of diabetic foot without critical ischemia. Ter Arkh. 2001;73(4):31–3.
pubmed: 11494443
pmcid: 11494443
Mozgovaya E, Pecherina L. Sulodexide efficacy in complex therapy and prevention of gestational toxicosis (gestosis) in patients with type 1 diabetes mellitus. Farmateka. 2006;3:128–33.
Olde Engberink RH, Vogt L. The renoprotective effects of sulodexide. Drug Des Devel Ther. 2016;10:1233–4. https://doi.org/10.2147/DDDT.S102814 .
doi: 10.2147/DDDT.S102814
pubmed: 27042014
pmcid: 4809327
Shustov SB. Controlled clinical trial on the efficacy and safety of oral sulodexide in patients with peripheral occlusive arterial disease. Curr Med Res Opin. 1997;13(10):573–82. https://doi.org/10.1185/03007999709113331 .
doi: 10.1185/03007999709113331
pubmed: 9327192
pmcid: 9327192
Apollonio A, Antignani PL, Di Salvo M, et al. A large Italian observational multicentre study on vascular ulcers of the lower limbs (Studio Ulcere Vascolari). Int Wound J. 2016;13(1):27–34. https://doi.org/10.1111/iwj.12216 .
doi: 10.1111/iwj.12216
pubmed: 24618175
pmcid: 24618175
Arcangeli A, Pedone T, Crescenti C, Ianni L. Microalbuminuria and type-II diabetes: clinical efficacy of sulodexide. Preliminary data. Minerva Cardioangiol. 2000;48(11 Suppl 2):72–3.
Piaggesi A, Abbruzzese L, Mattaliano C, et al. Sulodexide as adjunctive therapy in diabetic foot patients with critical limb ischemia treated with percutaneous transluminal angioplasty. Int J Low Extrem Wounds. 2014;13(2):103–9. https://doi.org/10.1177/1534734614534442 .
doi: 10.1177/1534734614534442
pubmed: 24861092
pmcid: 24861092
Gohel MS, Taylor M, Earnshaw JJ, Heather BP, Poskitt KR, Whyman MR. Risk factors for delayed healing and recurrence of chronic venous leg ulcers–an analysis of 1324 legs. Eur J Vasc Endovasc Surg. 2005;29(1):74–7. https://doi.org/10.1016/j.ejvs.2004.10.002 .
doi: 10.1016/j.ejvs.2004.10.002
pubmed: 15570275
pmcid: 15570275
Coccheri S, Bignamini AA. Pharmacological adjuncts for chronic venous ulcer healing. Phlebology. 2016;31(5):366–7. https://doi.org/10.1177/0268355515619562 .
doi: 10.1177/0268355515619562
pubmed: 26655886
pmcid: 26655886
Gambaro G. Discounting the efficacy of sulodexide in diabetic nephropathy is premature. Am J Kidney Dis. 2012;60(1):169–70. https://doi.org/10.1053/j.ajkd.2012.01.029 .
doi: 10.1053/j.ajkd.2012.01.029
pubmed: 22709598
pmcid: 22709598
Coccheri S. Game not over for sulodexide. Am J Kidney Dis. 2012;59(3):467.
pubmed: 22340910
doi: 10.1053/j.ajkd.2011.12.010
pmcid: 22340910
Rozita M, Mohd Shahrir M, Loo C, et al. Glycosaminoglycans (sulodexide) for resistant heavy proteinuria of chronic glomerulonephritides. Nephrology. 2008;13(Suppl 1):A55.
Kozlova L, Khokhlov R, Akhmedzhanov N. Clinical efficacy of glycosaminoglycans in patients with diabetes mellitus and ischemic heart disease. Rational Pharmacother Card. 2011;7(5):584–90.
doi: 10.20996/1819-6446-2011-7-5-584-590
Marcoux R, Larrat E, Taubman A, Wilson J. Screening for peripheral arterial disease. J Am Pharm Assoc (Wash). 1996;NS36:370–3.
doi: 10.1016/S1086-5802(16)30076-6
Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006;114(7):688–99. https://doi.org/10.1161/CIRCULATIONAHA.105.593442 .
doi: 10.1161/CIRCULATIONAHA.105.593442
pubmed: 16908785
Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7(2):128–39. https://doi.org/10.1016/S2213-8587(18)30314-0 .
doi: 10.1016/S2213-8587(18)30314-0
pubmed: 30635226
Inker LA, Heerspink HJL, Tighiouart H, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735–45. https://doi.org/10.1681/ASN.2019010007 .
doi: 10.1681/ASN.2019010007
pubmed: 31292197
pmcid: 6727261
Olde Engberink RH, Heerspink HJ, de Zeeuw D, Vogt L. Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies. Br J Clin Pharmacol. 2016;82(5):1351–7. https://doi.org/10.1111/bcp.13062 .
doi: 10.1111/bcp.13062
pubmed: 27412828
pmcid: 5061782
Bignamini AA, Matuška J. Sulodexide for the symptoms and signs of chronic venous disease: a systematic review and meta-analysis. Adv Ther. 2020;37(3):1013–33. https://doi.org/10.1007/s12325-020-01232-1 .
doi: 10.1007/s12325-020-01232-1
pubmed: 31989486
pmcid: 7089759
Gaddi A, Galetti C, Illuminati B, Nascetti S. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res. 1996;24(5):389–406. https://doi.org/10.1177/030006059602400501 .
doi: 10.1177/030006059602400501
pubmed: 8895043
Shang H-X, Zhao J-Y, Shen X, et al. The efficacy and safety of sulodexide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2016;9(7):12481–91.